Loading company…
Mysthera Therapeutics develops oral PIM kinase inhibitor treatments for autoimmune diseases.
Founded in 2023, Mysthera Therapeutics is based in Basel, Switzerland. It is developing oral treatments for autoimmune diseases including glomerulonephritis, rheumatoid arthritis and inflammatory bowel disease, using PIM kinase inhibitors. CEO Darren Cunningham leads the company. In August 2023, it raised USD 3.5 million in seed funding from Forty51 Ventures to advance preclinical inhibitors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in